🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Bench to bedside in ~7 years! Eyecyte-RPE is a completely indigenously developed product created through a patented and published technology. Thank you everyone who has been a part of this incredible journey! Jogin Desai Rajani Battu DBT-BIRAC C-CAMP

So proud to see our Chief Scientist Rajarshi Pal presenting our research on Oculo-cutaneous albinism at the prestigious Retinal Cell and Gene Therapy Innovation Summit in Seattle

Microphysiological Systems Bootcamp registration is live! CPHMS is back with the next edition of MPS Bootcamp, join us for an immersive experience with leading experts from C-CAMP, IISc, and Eyestem. Discover the speaker lineup! Link: forms.gle/NoUqNES8EJQrKH… Secure your spot!

📢 Coming Up! Microphysiological Systems Bootcamp 🗓️ August 19-24, 2024 📍 C-CAMP & IISc Bangalore Explore cutting-edge topics with experts: *Microfluidics & Organ-on-Chip by Dr. Karthik Mahesh from CCAMP. *Organoid Culture by Rajarshi Pal from Eyestem, a

Learn more about the progress of cell and gene therapy in India with clinical trials in eye disorder (Dry Age-related Macular Degeneration) and different hematological disorders. isctglobal.org/events/event-d… Eyestem Jogin Desai Centre for Stem Cell Research _ CMC _ inStem

So far so good, next cohort looks closer! Exciting times! modernretina.com/view/eyestem-c… Jogin Desai Rajani Battu C-CAMP Dr. Taslimarif Saiyed DBT-BIRAC

A big THANK YOU to all for supporting us through this exceptional journey and deepest gratitude to those patients who trusted our innovative cell product!! C-CAMP DBT-BIRAC ISER ARVO AAO Foundation Fighting Blindness EURETINA ICMR APAO

A therapy is only as useful as the surgeon's comfort with delivering it safely and effectively. Figuring out pain points/addressing them is key to ultimate market adoption. To quote Da Vinci "Simplicity is the ultimate sophistication"! One step closer Rajani Battu Rajarshi Pal

Curtain Raiser #IISF2024 Theme - Transforming India into an S&T driven Global Manufacturing Hub We hosted Dr Rajarshi Pal Co-Founder & Chief Scientist Eyestem to share the thrilling journey of establishing a #stemcelltherapy company IISF 2024 Department of Biotechnology CSIR-NIScPR

Dr Rajarshi Pal uncovered the need for therapy that #stemcell tech can provide in Dry Age-related Macular Degeneration (Dry AMD) & set out to generate the solution in 2017, conquering many challenges. Their lead product Eyecyte-RPE™️ now gives promising results in human trials!

4 out of 6 top Indian biotech companies leading the global healthcare revolution from the forefront are CCAMP startups as per the latest Labiotech.eu survey. labiotech.eu/best-biotech/b… Congrats #Bugworks, Zumutor Biologics Eyestem #Gangagen for making it to this list The 4 are

Delighted to announce interim results for our FIH trial for treatment of GA 1. No SAEs and minimal TEAEs, 2. Five out of Six patients had a improvement in vision (3-31 letters). 3. Noticeable decrease in RPE/PR defect areas 4. Structural changes in OCT linkedin.com/feed/update/ur…)

Delighted to announce interim results for our phase 1 to treat Geographic Atrophy No Serious Adverse Events reported Average improvement of 14.9 letters in ETDRS over 3-6 m Anatomical changes identified in almost all pts at 3 months Will explore further in Ph 2 in India/US

All 9 injections for phase 1 done !. So far, we have shown an average 14.9 letter improvement in vision for 6 patients over 3-6 months, anatomical correlations and no SAEs. Improvement in the quality of life of patients has been equally impressive.Look forward to Ph 2 in India/US

Happy to share that this paper from Eyestem is online! nature.com/articles/s4153… The study provides a unified benchmark for developing iPSC-based cell therapy in India, and offers a mechanistic framework to assess preclinical safety and efficacy Jogin Desai Rajani Battu

Feels surreal achieving a milestone that we have been dreaming of for the past 5 years! The trial demonstrated meaningful vision improvement (15.8 letters for 6 patients with poor vision in 6 months)while having no Serious Adverse Events. Onward to Ph 2! .expresshealthcare.in/news/eyestem-a…